These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 34782799)

  • 1. Comparison of remdesivir and favipiravir - the anti-Covid-19 agents mimicking purine RNA constituents.
    Al-Ardhi FM; Novotny L; Alhunayan A; Al-Tannak NF
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2022 Mar; 166(1):12-20. PubMed ID: 34782799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic dilemmas in addressing SARS-CoV-2 infection: Favipiravir versus Remdesivir.
    Negru PA; Radu AF; Vesa CM; Behl T; Abdel-Daim MM; Nechifor AC; Endres L; Stoicescu M; Pasca B; Tit DM; Bungau SG
    Biomed Pharmacother; 2022 Mar; 147():112700. PubMed ID: 35131656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative assessment of favipiravir and remdesivir against human coronavirus NL63 in molecular docking and cell culture models.
    Wang Y; Li P; Rajpoot S; Saqib U; Yu P; Li Y; Li Y; Ma Z; Baig MS; Pan Q
    Sci Rep; 2021 Dec; 11(1):23465. PubMed ID: 34873274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Efficacy of Remdesivir and Favipiravir in the Treatment of COVID-19 Patients: Scenario so far.
    Saini M; Rana M; Bhatti K; Das R; Mehta DK; Chidurala RM
    Curr Drug Res Rev; 2022; 14(1):11-19. PubMed ID: 34365935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-Membrane Interactions: Effects of Virus-Specific RNA-Dependent RNA Polymerase Inhibitors Remdesivir and Favipiravir on the Structure of Lipid Bilayers.
    Fischer M; Müller P; Scheidt HA; Luck M
    Biochemistry; 2022 Jul; 61(13):1392-1403. PubMed ID: 35731976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular Considerations of Remdesivir and Favipiravir in the Treatment of COVID-19.
    Shahrbaf MA; Tabary M; Khaheshi I
    Cardiovasc Hematol Disord Drug Targets; 2021; 21(2):88-90. PubMed ID: 34387172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tackling COVID-19 Using Remdesivir and Favipiravir as Therapeutic Options.
    Sreekanth Reddy O; Lai WF
    Chembiochem; 2021 Mar; 22(6):939-948. PubMed ID: 33031623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insights on the Quantitative Concurrent Fluorescence-Based Analysis of Anti-COVID-19 Drugs Remdesivir and Favipiravir.
    El-Awady M; Elmansi H; Belal F; Shabana RA
    J Fluoresc; 2022 Sep; 32(5):1941-1948. PubMed ID: 35771341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spectrofluorimetric quantitative analysis of favipiravir, remdesivir and hydroxychloroquine in spiked human plasma.
    Ramzy S; Abdelazim AH; Osman AO; Hasan MA
    Spectrochim Acta A Mol Biomol Spectrosc; 2022 Nov; 281():121625. PubMed ID: 35863184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity.
    Tsuji M
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can the Antivirals Remdesivir and Favipiravir Work Better Jointly? In Silico Insights.
    Parlak C; Alver Ö; Ouma CNM; Rhyman L; Ramasami P
    Drug Res (Stuttg); 2022 Jan; 72(1):34-40. PubMed ID: 34535038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus.
    Costanzo M; De Giglio MAR; Roviello GN
    Curr Med Chem; 2020; 27(27):4536-4541. PubMed ID: 32297571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthetic Attempts Towards Eminent Anti-viral Candidates of SARS-CoV.
    Kundu S; Sarkar D
    Mini Rev Med Chem; 2022; 22(2):232-247. PubMed ID: 34254915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An effective drug against COVID-19: reality or dream?
    Yaghoubi A; Amel Jamehdar S; Movaqar A; Milani N; Soleimanpour S
    Expert Rev Respir Med; 2021 Apr; 15(4):505-518. PubMed ID: 33215942
    [No Abstract]   [Full Text] [Related]  

  • 15. Favipiravir use in children with COVID-19 and acute kidney injury: is it safe?
    Ozsurekci Y; Oygar PD; Gürlevik SL; Kesici S; Ozen S; Kurt Sukur ED; Gülhan B; Topaloglu R; Bayrakci B; Cengiz AB
    Pediatr Nephrol; 2021 Nov; 36(11):3771-3776. PubMed ID: 34021797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Remdesivir (GS-5734) in COVID-19 Therapy: The Fourth Chance.
    Moirangthem DS; Surbala L
    Curr Drug Targets; 2021; 22(12):1346-1356. PubMed ID: 33267759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beneficial effect of combinational methylprednisolone and remdesivir in hamster model of SARS-CoV-2 infection.
    Ye ZW; Yuan S; Chan JF; Zhang AJ; Yu CY; Ong CP; Yang D; Chan CC; Tang K; Cao J; Poon VK; Chan CC; Cai JP; Chu H; Yuen KY; Jin DY
    Emerg Microbes Infect; 2021 Dec; 10(1):291-304. PubMed ID: 33538646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Remdesivir against COVID-19 and Other Viral Diseases.
    Malin JJ; Suárez I; Priesner V; Fätkenheuer G; Rybniker J
    Clin Microbiol Rev; 2020 Dec; 34(1):. PubMed ID: 33055231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency.
    Gordon CJ; Tchesnokov EP; Woolner E; Perry JK; Feng JY; Porter DP; Götte M
    J Biol Chem; 2020 May; 295(20):6785-6797. PubMed ID: 32284326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A complementary critical appraisal on systematic reviews regarding the most efficient therapeutic strategies for the current COVID-19 (SARS-CoV-2) pandemic.
    Kheirabadi D; Haddad F; Mousavi-Roknabadi RS; Rezaeisadrabadi M; Dehghan H; Fazlzadeh A
    J Med Virol; 2021 May; 93(5):2705-2721. PubMed ID: 33463727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.